Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. (RGNT): ~16 mo cash runway. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
16.1 months
D/E 0.61 · 0% dilution
N/A
N/A
N/A
N/A
A transparent, data-derived signal for Regentis Biomaterials Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$48.7M
Cash
$7.4M
Quarterly Burn
$1.4M
Runway
16.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Institutional Holdings
Source: SEC Form 13F · as of Dec 2025Institutional holders
1
Total value held
$70K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 10,412 | $70K |
Frequently asked questions
What is Regentis Biomaterials Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Regentis Biomaterials Ltd. has approximately 16.1 months of cash runway.
What is Regentis Biomaterials Ltd.'s market capitalization?
Regentis Biomaterials Ltd.'s market capitalization is approximately $48.7M.
Who is the CEO of Regentis Biomaterials Ltd.?
Dr. Ehud Geller Ph.D. is the chief executive officer of Regentis Biomaterials Ltd. (RGNT).
Get the full picture on Regentis Biomaterials Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.